Electric flying suit BMW created 300 kilometers per hour: BMW i, Designworks and air sports pioneer Peter Salzmann have introduced the first electric wingsuit flight, as Electrek picks up.
The project has been brewing for three years, when it began as a simple concept in the mind of the athlete.
During the jumps, Salzmann wore a conventional wingsuit to increase his glide ratio and cover more horizontal terrain before opening the parachute because, with the right material, impressive angles can be achieved.
Now, with a little electrical help, the athlete has managed to boost his wingsuit and fly, noticeably increasing his horizontal progress.
Thus, while users of a normal aerial suit can reach horizontal speeds close to 100 kilometers per hour (62 miles per hour), the electric exceeds 300 km/h (186 mph).
Electric flying suit BMW created 300 kilometers per hour
For the first Test Salzmann was launched from a helicopter at 3,000 meters along with two other operators of conventional wing suits over the mountains of his native Austria.
The 3 flew to a mountain peak that the users of the conventional apparatus surrounded, while the athlete accelerated and took off to the top, meeting the others on the other side.
The electric suit is powered through a battery and the entire system hangs from the front, at the height of the pilot's chest. The device reaches a power of 15 kilowatts (kW) divided between two 7.5 kW carbon impellers that rotate at a speed of 25,000 revolutions per minute (RPM) and generate a thrust of up to five minutes.
This artifact will be presented at the #NEXTGen event organized by BMW.
Electric flying suit BMW created 300 kilometers per hour
Why Pfizer's results are good news for other coronavirus vaccines
The week has awakened with the announcement that the vaccine developed by Pfizer and BioNTech showed to be effective preventing infections in 90% of cases, according to a statement issued by the company itself.
The results have yet to be published in a scientific journal study so that the community can examine the actual data, but the markets and the population have not taken long to celebrate the milestone.
The minister of Health, Salvador Illa, has assured that the European Union will soon sign agreements with the pharmaceutical company and Spain will receive 20 million doses that could immunize 10 million people.
In the face of widespread optimism, experts call for caution, pointing out that there are many unresolved questions and warning that, even if successful, the vaccine will not be available for mass distribution in the short term.
"We have to be cautious because these results, being good and hopeful, are very preliminary and the data have not been made public. Pfizer's announcement comments that the vaccine has a 90% efficacy at 7 days after the second vaccine dose. Seven days is a very short period of time to estimate the effectiveness of a vaccine. Hopefully that effectiveness will be maintained for weeks and months, " explains Dr. María Montoya, researcher of the Center for Biological Research Margarita Salas of the CSIC (CIB-CSIC) and member of the board of Directors of the Spanish Society of Immunology, to Business Insider Spain.
However, the company's results do not cease to be good news at a time when the number of confirmed cases worldwide exceeds 50 million and could also mean that the other coronavirus vaccines that are under development will achieve approval.
Despite the competition of a sector that is fighting for a market that could be worth many millions of dollars, the results of Pfizer and BioNTech offer hope to all companies and it is very likely that the results of the vaccine have been held in more of a host of other pharmaceuticals that are developing candidates against the COVID-19.
Pfizer's vaccine has a specific target when it comes to attacking the virus: the S protein, a spicule on the surface of the coronavirus.
"There was always a discussion: is protein s the right target? Well, now we know it's the right goal," Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, told STAT on Monday. "Therefore, not only is it immediate good news, but it is optimistic about what is going to be deployed in the coming months with the other vaccines."
In fact, all vaccines that are being accelerated by Operation Warp Speed attack the virus, as well as the most advanced Spanish project of the CSIC.
The chosen target is a protein that is on the surface of the virus and with which it can penetrate into cells. "With that vaccine what we try is that it can not get in," explained Juan García Arriaza, principal investigator of a vaccine against coronavirus at the Spanish center, in an interview with Business Insider Spain.
However, as more was known about the virus, the advisability of targeting only this protein was questioned.
When assessing the effectiveness that the AstraZeneca vaccine could have, Isabel Sola, titular scientist and co-director together with Luis Rincanes of the coronavirus Laboratory of the National Biotechnology Center (CNB) of the Superior Council of Scientific Research (CSIC), pointed out in another interview with Business Insider Spain as a possible drawback the fact that the candidate only focused on attacking the
The scientist noted that the S protein has been shown to be relevant for the production of neutralizing antibodies, but that the cellular response is becoming more relevant.
However, if Pfizer's data is confirmed —on which there are still many questions to be solved— it could alleviate the doubts of many manufacturers as to whether they have succeeded in their strategy.
"We believe that these interim results also increase the likelihood of success of other candidate vaccines against COVID-19 that use a similar approach," assures CEPI CEO Richard Hatchett in a statement collected by STAT.
"In a vaccine there are two components, a vaccine vehicle and the protein or antigen that comes from the pathogen, in this case SARS-CoV-2. These results are hopeful for vaccines that use the S of SARS-CoV-2, even with another vaccine vehicle," confirms Dr. Montoya, who nevertheless warns that more vaccines must be developed "because we do not know the duration" and it will be difficult to vaccinate everyone.
At the beginning of the pandemic, a battle appeared to arise that confronted an innovative genetic technology with the traditional method of attenuated viruses.
The modern American biotech, which made headlines after starting human trials 63 days after the virus genome was sequenced, was betting on genetics with a messenger RNA platform that had never produced a vaccine approved for human use.
By betting on BioNTech, Pfizer also supported the bet on messenger RNA and their good results suggest that they will be the first to market a vaccine of this type and offer hope for other candidates of this type.
"In the event that the results are sufficient for the drug agencies of each country to approve it, it would be the first vaccine with a mRNA construction, so it would open the doors to other vaccines based on this concept," explains Dr. Montoya.
"It validates the mRNA platform," Anthony Fauci points out to STAT. "Everything points to the fact that unless something strange happens, Moderna will probably have similar results."
In addition, the technology behind this vaccine allows accelerated manufacturing and be more prepared for the following pandemics.
"It would be very interesting if messenger RNA vaccines worked," acknowledged Adolfo García-Sastre, director of the Institute of Global Health and Emerging Pathogens linked to the Monte Sinai Hospital in New York, also in another conversation with Business Insider Spain.
With Pfizer preparing to apply for emergency clearance, the possibility of them doing so is becoming more and more real.